Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light therapy eases dry eyes after LASIK, study finds

NCT ID NCT07181668

Symptom relief Sponsor: Grigore T. Popa University of Medicine and Pharmacy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a gentle light treatment (low-level light therapy) given before and after Femto-LASIK eye surgery. 61 adults without prior dry eye received either real light therapy or a sham treatment. Those who got the real treatment had more stable tears and fewer dry eye symptoms over 3 months, with no side effects. The approach appears safe and may help people recover more comfortably after LASIK.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

61 people

The number who actually took part.

Started

Aug 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years. * Scheduled for bilateral Femto-LASIK surgery for refractive error correction. * Willing and able to provide written informed consent. * Ability and willingness to comply with all study procedures and follow-up visits. * Baseline ocular surface within normal limits (no pre-existing dry eye or ocular surface disease) Exclusion Criteria: * Prior diagnosis of ocular surface disease (OSD) or dry eye disease (DED). * History of ocular surgery in either eye. * Presence of ocular comorbidities such as glaucoma, corneal dystrophies, or active ocular infections. * Current or regular use of topical ocular treatments, including lubricants, corticosteroids, cyclosporine, or other drugs for DED or OSD. * Use of instrumental therapies for ocular surface or tear film optimization (e.g., thermal pulsation, IPL). * Systemic treatments known to influence tear production (e.g., diuretics, antihistamines, antidepressants, hormone replacement therapy). * Autoimmune diseases affecting the eyes, including Sjögren's syndrome or rheumatoid arthritis. * Any intraoperative or postoperative complications that could interfere with ocular surface assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Meibomian Gland Dysfunction dry eye syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye Meibomian gland dysfunction (disorder) Ocular surface disease

Contacts and locations

Locations

  • University of Medicine and Pharmacy "Grigore T. Popa" Iași,

    Iași, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.